CGTLive’s Weekly Rewind – November 4, 2022
Review top news and interview highlights from the week ending November 4, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. RDEB Cell Therapy Improves Wound Healing and Reduces Pain
Abeona has announced topline results from its phase 3 VIITAL study of EB-101.
2. REGENXBIO’s Gene Therapy Improves Diabetic Retinopathy Disease Severity
Updated data from the ALTITUTE trial were presented at the 55th ARS meeting in Pasadena, CA.
3. Paul Melmeyer on Regulatory Advocacy for Patients With Neuromuscular Diseases
The vice president of Public Policy & Advocacy of the Muscular Dystrophy Association discussed the organization’s goals and strategies in educating regulatory decision-makers.
4. MB-106, A CD20-CAR T, Yields 100% ORR in Waldenstrom Macroglobulinemia
Data from the first 2 patients were presented at the IWWM 2022 meeting.
5. PR001 Hopes to Address Underlying Mutations in Neuronopathic Type 2 Gaucher Disease
In this feature, CGTLive highlights the PROVIDE trial of PR001 for Gaucher Awareness Month.
Evaluating Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple Myeloma
November 21st 2024Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center, discussed interim data from the phase 1/1b clinical trial evaluating Poseida's CAR-T.
World Pancreatic Cancer Day 2024: Looking Back at Progress in Cell and Gene Therapy
November 21st 2024In observance of World Pancreatic Cancer Day, held on the third Thursday of November each year, we took a look back at the past year's news in cell and gene therapy for pancreatic cancer indications.
